stockportfolio.pro
Stocks / HAE vs OGN
HAE vs OGN
Haemonetics Corporation and Organon & Co. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Haemonetics Corporation (HAE) | Organon & Co. (OGN) | |
|---|---|---|
| Market cap | $3.6B | $3.5B |
| Revenue (latest FY) | $1.33B | $6.22B |
| Net income (latest FY) | $97.31M | $187.00M |
| Revenue growth (5y CAGR) | 8.9% | -1.0% |
| Net margin | 7.3% | 3.0% |
| Return on equity | 12.2% | 24.9% |
| P/E ratio | 38.4 | 14.4 |
| Dividend yield | — | 0.6% |
| Profitable years (of last 10) | 9 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HAE — free Open OGN — freeFrequently asked questions
Which is bigger, HAE or OGN?
Haemonetics Corporation is larger by market capitalization — $3.6B versus $3.5B.
Which grows faster, HAE or OGN?
Over the last five fiscal years, Haemonetics Corporation grew revenue faster — 8.9%/yr versus -1.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.